BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 12838295)

  • 41. Comparison of CT colonography, colonoscopy, sigmoidoscopy and faecal occult blood tests for the detection of advanced adenoma in an average risk population.
    Graser A; Stieber P; Nagel D; Schäfer C; Horst D; Becker CR; Nikolaou K; Lottes A; Geisbüsch S; Kramer H; Wagner AC; Diepolder H; Schirra J; Roth HJ; Seidel D; Göke B; Reiser MF; Kolligs FT
    Gut; 2009 Feb; 58(2):241-8. PubMed ID: 18852257
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Colorectal cancer mass-screening: estimation of faecal occult blood test sensitivity, taking into account cancer mean sojourn time.
    Launoy G; Smith TC; Duffy SW; Bouvier V
    Int J Cancer; 1997 Oct; 73(2):220-4. PubMed ID: 9335446
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors affecting compliance in faecal occult blood testing: a cluster randomized study of the faecal immunochemical test versus the guaiac faecal occult test.
    Birkenfeld S; Belfer RG; Chared M; Vilkin A; Barchana M; Lifshitz I; Fruchter D; Aronski D; Balicer R; Niv Y; Levi Z
    J Med Screen; 2011; 18(3):135-41. PubMed ID: 22045822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patterns of uptake in a biennial faecal occult blood test screening programme for colorectal cancer.
    Steele RJ; McClements PL; Libby G; Carey FA; Fraser CG
    Colorectal Dis; 2014 Jan; 16(1):28-32. PubMed ID: 24034143
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial.
    Federici A; Giorgi Rossi P; Borgia P; Bartolozzi F; Farchi S; Gausticchi G
    J Med Screen; 2005; 12(2):83-8. PubMed ID: 15949119
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incidence of interval cancers in faecal immunochemical test colorectal screening programmes in Italy.
    Giorgi Rossi P; Carretta E; Mangone L; Baracco S; Serraino D; Zorzi M;
    J Med Screen; 2018 Mar; 25(1):32-39. PubMed ID: 28195508
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study.
    Levi Z; Birkenfeld S; Vilkin A; Bar-Chana M; Lifshitz I; Chared M; Maoz E; Niv Y
    Int J Cancer; 2011 May; 128(10):2415-24. PubMed ID: 20658527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy.
    Brenner H; Tao S
    Eur J Cancer; 2013 Sep; 49(14):3049-54. PubMed ID: 23706981
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Colorectal cancer in a second round after a negative faecal immunochemical test.
    Bujanda L; Sarasqueta C; Castells A; Pellisé M; Cubiella J; Gil I; Cosme A; Arana-Arri E; Mar I; Idigoras I; Portillo I;
    Eur J Gastroenterol Hepatol; 2015 Jul; 27(7):813-8. PubMed ID: 25856688
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diagnostic yield of a one sample immunochemical test at different cut-off values in an organised screening programme for colorectal cancer.
    Hamza S; Dancourt V; Lejeune C; Bidan JM; Lepage C; Faivre J
    Eur J Cancer; 2013 Aug; 49(12):2727-33. PubMed ID: 23601670
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know.
    Tinmouth J; Lansdorp-Vogelaar I; Allison JE
    Gut; 2015 Aug; 64(8):1327-37. PubMed ID: 26041750
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Faecal occult blood screening: knowledge, attitudes, and practice in four Hong Kong primary care clinics.
    Tam TK; Ng KK; Lau CM; Lai TC; Lai WY; Tsang LC
    Hong Kong Med J; 2011 Oct; 17(5):350-7. PubMed ID: 21979470
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of the performance of guaiac-based and two immunochemical fecal occult blood tests for identifying advanced colorectal neoplasia in Taiwan.
    Ou CH; Kuo FC; Hsu WH; Lu CY; Yu FJ; Kuo CH; Wang JY; Wu MT; Shiea J; Wu DC; Hu HM
    J Dig Dis; 2013 Sep; 14(9):474-83. PubMed ID: 23701988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Colorectal cancer mass screening event utilising quantitative faecal occult blood test.
    Chew MH; Suzanah N; Ho KS; Lim JF; Ooi BS; Tang CL; Eu KW
    Singapore Med J; 2009 Apr; 50(4):348-53. PubMed ID: 19421676
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcomes of faecal occult blood tests requested outside the UK National Bowel Cancer Screening Programme.
    McDonald R; Tomlins A; Smith S; Harmston C
    J Clin Pathol; 2013 Apr; 66(4):330-4. PubMed ID: 23288919
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2009 Feb; 29(4):450-7. PubMed ID: 19035980
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Basic variables at different positivity thresholds of a quantitative immunochemical test for faecal occult blood.
    Castiglione G; Grazzini G; Miccinesi G; Rubeca T; Sani C; Turco P; Zappa M
    J Med Screen; 2002; 9(3):99-103. PubMed ID: 12370319
    [TBL] [Abstract][Full Text] [Related]  

  • 59. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
    Lieberman DA; Weiss DG;
    N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.